USFDA concludes cGMP inspection at Cipla’s Bangalore facility
27th Jan 2020

United States Food and Drug Administration (USFDA) has concluded a cGMP inspection at Cipla’s API manufacturing facility in Bommasandra, Bangalore from January 20 - 24, 2020. The inspection ended with 4 observations which were procedural in nature and none of which were repeat or related to data integrity.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.